Advances in digital technologies are promising to revolutionize the delivery of medicine by introducing novel digital therapeutics and digital companion devices for existing therapies, enabling patient-centric clinical decision-making and research, bringing Point-of-Care to the patient with connected diagnostics, and ultimately impacting patient outcomes. The Inaugural Digital Medicine conference program will convene Digital Health thought leaders to discuss the latest technologies, applications and implementation strategies in the rapidly evolving field of Digital Medicine.

Final Agenda

Sunday, March 1

2:00 - 5:00 pm Afternoon Short Courses*

*Separate registration required

5:30 - 8:30 Dinner Short Courses*

*Separate registration required

Monday, March 2

8:00 - 11:00 am Morning Short Courses*

*Separate registration required

10:30 Conference Program Registration Open

DIGITAL HEALTH AT “BIG TECH”

11:45 Organizer’s Opening Remarks

Julia Boguslavsky, Executive Director, Conferences, Cambridge Healthtech Institute

11:50 Chairperson’s Remarks

Thomas Kluz, MS, General Partner, dRx Capital; Head, Healthcare Investing, Qualcomm Ventures


11:55 KEYNOTE PRESENTATION: How Is Wearable-Driven Digital Health Shaping Non-Critical Care?

Kuppuraj_RaviRavi Kuppuraj, PhD, CEO, Digital Innovator, Connected Sensing, Philips

Consumer wearable devices have already begun to reshape our general experience by putting people in the driver seat and back in charge of their healthcare – and now the healthcare industry has not only begun to see the same potential with clinical wearables, but they are becoming more widely adopted and sought after to address real concerns, like providing increased mobility for patients and decreasing costs for healthcare systems in non-critical care settings.

12:15 pm KEYNOTE PRESENTATION: AI and Its Disruptive Implications for Healthcare

Gough_ChrisChris Gough, General Manager, Health & Life Sciences, Intel Corporation

In this talk, we will explore the disruptive potential of AI for the healthcare industry. This will include market insights, real-world examples of deployments and use cases in healthcare from around the world, and practical guidance for how to prepare your organization to take advantage of these capabilities.

ClearView-Healtchare-Partners 12:35 KEYNOTE PRESENTATION: Forging New Paths for the Digital Revolution in Healthcare

Mathews_CharlesCharles Mathews, Principal, ClearView Healthcare Partners

Digital health technology is not only fostering the development and deployment of novel tools that provide innovative clinical information and interventions but it is also raising questions about commercialization, reimbursement, and value creation.  In this session, we will discuss the unique ways in which digital health can be leveraged (e.g., prevention, disease management, therapeutic, etc.) and weigh the trade-offs between business models (e.g., payer reimbursed, B2B, etc.). We will also provide insights into strategies that harness the unique nature of digital tools and create a virtuous cycle that fosters innovation.

12:55 KEYNOTE PANEL DISCUSSION: How Is “Big Tech” Implementing Digital Health?

Kluz_ThomasModerator: Thomas Kluz, MS, General Partner, dRx Capital; Head, Healthcare Investing, Qualcomm Ventures


Gough_ChrisPanelists: Chris Gough, General Manager, Health & Life Sciences, Intel Corporation


Kuppuraj_RaviRavi Kuppuraj, PhD, CEO, Digital Innovator, Connected Sensing, Philips

 

 

Charles Mathews, Principal, ClearView Healthcare Partners

 

Joe Ritchie, Chief Commercial Officer, SensoryData Corporation


 

1:30 Digital Health Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own

2:05 Session Break

DIGITAL THERAPEUTICS

2:30 Chairperson’s Remarks

Joris van Dam, PhD, Head, Digital Therapeutics, Novartis Institutes for BioMedical Research

2:35 Digital Therapeutics in Pharma

Van_Dam_JorisJoris van Dam, PhD, Head, Digital Therapeutics, Novartis Institutes for BioMedical Research

The Digital Therapeutics Alliance often refers to digital therapeutics as “a new class of medicine.” In this talk, we will explore the opportunities and challenges of integrating digital therapeutics as a new therapeutic class within a more traditional medicines portfolio based on our experience at Novartis and based on our successes and challenges in our partnership with Pear Therapeutics.

3:00 Pharma: The Five Questions You Need to Be Able to Answer about Your Digital Therapeutic

Geoff McCleary, Director, Digital Health & Therapeutics, PricewaterhouseCoopers

3:25 Prescription Digital Therapeutics: Establishing a New Therapeutic Class

Waldron_AlexAlex Waldron, Chief Strategy Officer, Pear Therapeutics

Prescription digital therapeutics (PDTs) are a new modality of therapeutic providing efficacy in many dis-ease areas previously untreated, or only partially treated.

3:50 Digital Medicine Extends to Peer Support

Kaufman_AdamAdam Kaufman, PhD, President & CEO, Canary Health

So many of the outcomes we care about to improve health and impact costs are driven by individuals’ behaviors, emotions, relationships, lifestyle and system navigation. This talk will highlight how evidence-based, digital, peer-to-peer support groups are extending care models to engage individuals with chronic conditions and cost-effectively enable peers to support each other, often in ways that complement traditional provider-driven care.

4:15 Q&A with the Speakers

4:25 Refreshment Break and Transition to Plenary Keynote


PLENARY KEYNOTE SESSION

(please see Keynote pages for details)

4:35 Welcome Remarks

Cindy Crowninshield, RDN, LDN, HHC, Executive Event Director, Cambridge Healthtech Institute

4:45 PLENARY KEYNOTE INTRODUCTION

Thomas Westerling-Bui, PhD, Senior Scientist, Regional Business Development, Aiforia

5:00 PLENARY KEYNOTE PRESENTATION: High-Performance Medicine

Eric Topol, MD, Founder and Director, Scripps Research Translational Institute (SRTI); Author, Deep Medicine: How Artificial Intelligence Can Make Healthcare Human Again

 

 

 

 

6:00 Grand Opening Reception in the Exhibit Hall with Poster Viewing, Speed Networking, Book Signing, and Meetup Group

7:30 End of Day

Tuesday, March 3

7:30 am Registration Open and Morning Coffee

DIGITAL HEALTH AT BIG PHARMA

8:00 Organizer’s Remarks

Julia Boguslavsky, Executive Director, Conferences, Cambridge Healthtech Institute

8:05 Chairperson’s Remarks

Geoff McCleary, Director, Digital Health & Therapeutics, PricewaterhouseCoopers


8:10 NEW KEYNOTE PRESENTATION: Digital Health Technologies for Mental Health

Chan_Yu-FengYu-Feng (Yvonne) Chan, MD, PhD, Senior Director, Medical Affairs for Digital Medicine, Otsuka

We're in the midst of a mental health crisis in the US and worldwide, with 20% of US adults experiencing some form of mental illness and an acute shortage of mental health professionals results in severe unmet needs and high economic costs. Digital health technologies may offer new options for mental health treatment. This talk explores whether this technology enhanced, multi-stakeholder, multi-disciplinary approach could help drive better patient outcomes.

8:30 KEYNOTE PRESENTATION: The Experimental Science behind Empowering Teams

Lasmanis_MattMatt Lasmanis, Vice President, Technology, GlaxoSmithKline

How do you make large organizations more agile, customer-centric and flexible? There are myriad answers, and GSK is using their science focused approach to guide the way. Matt Lasmanis, VP of Pharma US Tech, is leading the transformation of the GSK tech culture, empowering his teams to achieve outcomes with clarity over certainty. In the presentation, Matt will discuss: 1) leading experiment-driven, data and product-oriented teams and avoiding non-failure driven culture, 2) empowering teams to make decisions closer to the ground, 3) shifting mindset of teams to be more agile and business-minded.

8:50 Making Personalized Healthcare a Reality: The Potential of Digital Health Technologies

Mary Beattie, MD, MAS, Global Group Medical Director, Personalized Health Care, Roche/Genentech

At Roche, we are working collaboratively to develop Digital Health solutions that aim to improve patient outcomes at each stage of the care continuum. I will discuss how these initiatives can enhance patient care, from early diagnosis to remote monitoring. Digital Health solutions are central to our Personalized Healthcare vision.

9:10 KEYNOTE PANEL DISCUSSION: How Is “Big Pharma” Implementing Digital Health?

Moderator: Geoff McCleary, Director, Digital Health & Therapeutics, PricewaterhouseCoopers


Panelists:


Van_Dam_JorisJoris van Dam, PhD, Head, Digital Therapeutics, Novartis Institutes for BioMedical Research

 

 

Mary Beattie, MD, MAS, Global Group Medical Director, Personalized Health Care, Roche/Genentech



Chan_Yu-FengYu-Feng (Yvonne) Chan, MD, PhD, Senior Director, Medical Affairs for Digital Medicine, Otsuka


 

9:40 Refreshment Break in the Exhibit Hall with Poster Viewing, Speed Networking, Book Signing, and Meetup Group

DIGITAL BIOMARKERS AND ENDPOINTS

10:40 Chairperson’s Remarks

Dan Karlin, MD, CEO, HealthMode

10:45 Digital Measurement in Clinical Trials: Fitting the Tool to the Question

Karlin_DanielDan Karlin, MD, CEO, HealthMode

Measurement in clinical trials is progressing from intermittent and imprecise, to highly granular and continuous. Making sense of this progression requires understanding the past/current means of measurement, the process for moving toward better measures, and having a vision for what the future might hold. Using four examples from our work, Dr. Karlin will address past, present, and potential future states in cough, bowel habits, agitation, pain, and performance status in oncology.

11:05 Digital Measures for Neurological Disorders

Dorsey_RayRay Dorsey, MD, David M. Levy Professor, Neurology; Director, CHeT, University of Rochester

Current measures for neurological disorders are subjective, episodic, and insensitive. Consequently, we have no highly effective therapies for Alzheimer’s disease, the most effective therapy for Parkinson’s is more than 50 years old, and many rare neurological disorders have no treatments at all. Smartphones, wearable sensors, and newer technologies can provide objective, frequent, sensitive assessments in real-world settings. The result could accelerate development of new drugs for the world’s leading source of disability and improved care for millions.

11:25 Uncovering the Potential of Wearable Devices for Identifying and Monitoring Neurological Events and Disease Progression

Yang_JianJian Yang, MD, Senior Director, Digital Health, Eli Lilly

This presentation will dive into findings from research on recent digital neurology research conducted with consumer devices and sensors. It will share how these devices could eventually equip consumers with tools to support early disease detection and progression and share key insights on how these may apply to other chronic conditions.

11:45 The Pursuit of Novel Digital Endpoints: What Is It? Learning & Considerations

Crouthamel_MichelleMichelle Crouthamel, PhD, MSc, DBA, Director, Digital Health & Innovation, AbbVie


VivoSense 12:05 pm Delivering a Digital Biomarker for a Regulated Trial in Rare Disease

Tabakin_DudleyDudley Tabakin, CEO, VivoSense

VivoSense is the first analytics company to develop novel digital biomarkers from wearable sensor data which constitute primary and secondary clinical endpoints in regulated international pharmaceutical trials. Several of these studies are in rare disease indications, and have reached the open-label phase of development at top-ten pharma.

12:35 Session Break

12:40 Digital Health Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own

1:20 Refreshment Break in the Exhibit Hall with Poster Viewing, Speed Networking, Book Signing, and Meetup Group

2:00 Breakout Discussions in the Exhibit Hall (please click here for details)

3:00 Transition to Conference Programs

REGULATORY STRATEGIES FOR DIGITAL MEDICINE

3:15 Chairperson’s Remarks

Michael Benecky, PhD, Senior Director, Global Regulatory Affairs, Precision & Digital Medicine, GlaxoSmithKline

3:20 Regulatory Considerations during Mobile Medical App Development for Commercial and Clinical Trial Use

Benecky_MichaelMichael Benecky, PhD, Senior Director, Global Regulatory Affairs, Precision & Digital Medicine, GlaxoSmithKline

Mobile medical apps are defined as medical devices from their intended use. Mobile medical app regulation is health risk-based to balance patient safety and barriers to technological innovation. Medical device patient risk analysis is a critical prerequisite prior to sensor/app inclusion within a clinical trial. Key components of quality management systems for mobile medical apps include: software requirements/specifications, user acceptance testing, software postmarket surveillance, software version control and medical device adverse event reporting.

3:50 Opportunities and Challenges in the Digital Landscape of Regulated and Non-Regulated Products

Oppenheimer_DarinDarin Oppenheimer, Executive Director, Regulatory Affairs & Digital Health Solutions, Merck

Digital Health continues to make inroads in various applications within the pharmaceutical industry. From standalone mobile apps, connected products, as well as applications in clinical trials, the opportunities are evolving as we speak. The regulatory landscape for digital solutions also continues to evolve, as MoH’s such as FDA and EMA continue to put out guidance and recommendations on how best to manage this rapidly changing area, taking risk into account. In this talk, we will lay the foundation from regulatory perspective on the past, present, and future of digital health solutions.

4:20 Regulatory Strategies for Digital Medicine

Andrew C. Fish, JD, Chief Strategy Officer, AdvaMed Center for Digital Health

4:50 Spring Fling Celebration in the Exhibit Hall with Poster Viewing, Speed Networking, Book Signing, and Meetup Group

6:00 End of Day

6:30 - 9:30 Dinner Short Courses*

*Separate registration required

Wednesday, March 4

6:45 am Registration Open

7:00 BREAKFAST PANEL DISCUSSION: The Time is NOW: Creating Meaningful Change for Women in the Workplace (Sponsorship Opportunity Available)

(please see Women in Science page for details)

Toft_RobinModerator: Robin Toft, Author of WE CAN, The Executive Woman’s Guide to Career Advancement; Founder and Chairman, Toft Group Executive Search


Samuels_CamillePanelists: Camille Samuels, MBA, Partner, Venrock


Hastings_PaulPaul Hastings, President and CEO, Nkarta Therapeutics, Inc


Wright_TerryTeresa L. Wright, MD, Staff Physician, Medicine, San Francisco Veterans Administration


DIGITAL TOOLS ENABLING CLINICAL TRIALS, RESEARCH, AND REAL-WORLD EVIDENCE

8:00 Chairperson’s Remarks

Ashish Atreja, MD, MPH, Assistant Professor, Chief Innovation Officer, Medicine, Icahn School of Medicine at Mount Sinai

8:05 A Platform Approach to Digital Transformation and Real-World Evidence

Atreja_AshishAshish Atreja, MD, MPH, Assistant Professor, Chief Innovation Officer, Medicine, Icahn School of Medicine at Mount Sinai

The practice of medicine is exponentially evolving. This evolution is fueled by value-based transformation and incentives that are aligning for continuous, proactive care, within and outside the four walls of the hospitals. To address this need, the new generation of startups is leveraging disciplines like data science, informatics, digital medicine, genomics, and AI; but this is creating a problem of plenty. In spite of more than 350,000 mobile apps for healthcare, less than 4% of patients are recommended apps by providers today.

8:25 NEW: Wearable Technologies for Remote Data Collection in Clinical Trials

Elena Izmailova, PhD, CSO, Koneksa Health

8:45 Unleashing the Potential of ML in Clinical Development

Holen_KyleKyle Holen, MD, Head, Development Design Center, AbbVie

Kyle will discuss the latest techniques his team has been using in attempts to solve some of the biggest challenges in drug development today, including site selection challenges, patient dropouts, and placebo enrollment. He will share some of the successes and failures along their journey as well as a future look at new areas where machine learning can help us design and execute on more efficient and rapid clinical trials.

9:05 Importance of Reorientation of Digital Medicine Product and Service Designs to Focus on the Patient as an Individual Consumer – Consumer-Oriented Patient Engagement Strategies

Pallapothu_RajRaj Pallapothu, Professor & Health Care Tech Industry Lead, University of Texas, Dallas

This presentation will cover: 1) new-generation digital biomarkers; 2) wearables in clinical trials; 3) evolving connected platforms and services (patient as consumer); 4) emerging digital study design and underlying study protocol changes; and 5) growing need for adaptive clinical trials and underlying importance aligned with consumerization.

9:25 Q&A with the Speakers

9:40 Refreshment Break in the Exhibit Hall with Poster Viewing, Speed Networking, Book Signing, and Meetup Group

BUILDING DIGITAL HEALTHCARE

10:40 Chairperson’s Remarks

Asif Dhar, Chief Health Informatics Officer, Principal, Deloitte Consulting LLP


10:45 KEYNOTE PRESENTATION: Harmonizing Healthcare Innovation for Better, Faster Transformation

Anderson_LeighLeigh Anderson, President of Performance Services, Premier, Inc.

Leigh Anderson, Premier’s President of Performance Services, will address the evolving healthcare ecosystem and how technological innovation including the application of artificial intelligence and machine learning must occur using a collaborative framework in order to quickly meet our goals of providing more coordinated, patient-centric and high-quality care.

11:10 KEYNOTE PRESENTATION: Smart Health Communities

Dhar_AsifAsif Dhar, Chief Health Informatics Officer, Principal, Deloitte Consulting LLP

This presentation will cover how digital disruptions are going to completely change the way we live and empower communities to battle disease and create abundant wellness.


11:35 KEYNOTE PANEL DISCUSSION: Building Digital Healthcare

Dhar_AsifModerator: Asif Dhar, Chief Health Informatics Officer, Principal, Deloitte Consulting LLP


Anderson_LeighPanelists: Leigh Anderson, President of Performance Services, Premier, Inc.


Mattison_JohnJohn Mattison, MD, Chief Medical Information Officer, emeritus, Kaiser Permanente


Jensen_ClausClaus Jensen, PhD, Chief Digital Officer & Head of Technology, Memorial Sloan Kettering Cancer Center


Laura Yecies, Digital Health Entrepreneur, Advisor, RX.Health, Akili Interactive



 

12:15 pm Session Break

12:50 Digital Health Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own

1:20 Refreshment Break in the Exhibit Hall with Last Chance Poster Viewing, Speed Networking, Book Signing, and Meetup Group

PATIENT CENTRICITY: DIGITAL MEDICINE = PERSONALIZED MEDICINE

2:00 Chairperson’s Remarks

Adrian Chernoff, Former Worldwide Vice President, Global Head of Research and Development, Johnson and Johnson

2:05 Wearables and Health

Snyder_MichaelMichael Snyder, PhD, Stanford W. Ascherman Professor & Chair, Department of Genetics; Director, Center for Genomics & Personalized Medicine, Stanford University

We have been using smart watches and continuous glucose monitoring to track people’s health and find early signs of disease.

2:25 Patient-Centricity, the Future to Enabling Digital Health

Chernoff_AdrianAdrian Chernoff, Former Worldwide Vice President, Global Head of Research and Development, Johnson and Johnson

Payers, providers and patients are beginning to encounter changes to the healthcare landscape with the introduction of new digital tools. As we shift into this new reality a key component will be to put the patient at the center shifting the relationship dynamics in how we deliver digital applications and build digital ecosystems to meet the growing needs of patients at any stage of care from healthcare, home care or self-care.

VIRTUAL REALITY IN MEDICINE

2:45 The Power and Potential of VR Medicine

Ramsay Brown, Director, Product Science, AppliedVR

With over 30 years of clinical research, the healthcare industry has embraced virtual reality (VR). Today, rapidly advancing mobile technology yielding ever more immersive experiences at a lower cost, is driving the use of VR beyond research environments into the clinical trenches and patient homes. Therapeutic VR is a promising new modality with the potential to treat serious and debilitating medical conditions, including pain - one of the most widely studied of all disease areas to date - by delivering a low-risk, non-pharmacological intervention.

3:05 Virtual Worlds, Real Results: How VR Is Transforming Healthcare

Rose_HowardHoward Rose, MEd, CEO & Co-Founder, Firsthand Technology

Howard will share the compelling evidence from clinical applications of VR therapy. VR's potential to induce deep changes in the brain unlocks new therapies for challenging conditions and populations. Propelled by the tsunami of consumer technologies, VR is poised to be the engine for personalized medicine that will fundamentally transform our health and the healthcare industry. 

3:25 Close of Conference

Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag


Premier Sponsors

AWS
Asuragen

Discovery-Life-Sciences

L7-informatics

NeoGenomics

Redbud-Labs

Roche

Stilla


ximedica